Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Antonio Gutierrez
Institutions:
Health Research Institute of the Balearic Islands,
Hospital Universitario Son Espases
Observed institutions:
Health Research Institute of the Balearic Islands,
Hospital Universitario Son Espases
ORCID:
0000-0001-9062-077X
Observed ORCID:
0000-0001-9062-077X
OpenAlex ID:
A5137572558
Gemcitabine plus selinexor in selective advanced sarcomas: a phase I of the Spanish group for research on sarcoma study
2026
·
Javier Martin-Broto
, Antonio Casado
, et al.
·
Nature Communications
·
3
PDF
IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort
2026
·
Javier Martin-Broto
, Sandra J. Strauss
, et al.
·
癌症:英文版
·
2
Initial report from the SAR-TRACK (SELNET) registry: a multicentric international retrospective analysis on the quality of the management of limb and trunk wall soft-tissue sarcomas (2012–2022) in Ibero-American countries
2026
·
Javier Martin-Broto
, Victor Castro
, et al.
·
The Lancet Regional Health - Americas
·
1
Supplementary Table S3 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Supplementary Table S1 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Supplementary Table S2 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Data from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Supplementary Figure S1 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Supplementary Figure S2 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Real‐world resource utilization, toxicity management, and efficacy outcomes of CD20 × CD3 bispecific antibodies in B‐cell lymphoma: A study from the GELTAMO network
2026
·
Mariana Bastos‐Oreiro
, Gloria Iacoboni
, et al.
·
HemaSphere
Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
·
Clinical Cancer Research
PDF
Show more works
View as search
Works count:
11
Citation count:
6
H-index:
2
I10-index:
Year
Topic
Type